EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥ 65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025)

Francisco Mercado, Sumi Akter, Aoi Ogawa, Subrahmanyan Valadi Ramakrishnan, Reannon Suzuki

Journal of Dementia and Alzheimer's Disease · 09.05.2026 · 3 (2) · 24

DOI: 10.3390/jdad3020024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Dementia and Alzheimer's Disease, online erschienen am 09.05.2026. Verfasst von Francisco Mercado und 4 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Delirium in older adults is strongly associated with and can predate dementia. While GLP-1 receptor agonists (GLP-1 RAs) may provide neuroprotective benefits, their role in reducing dementia risk among older patients with type 2 diabetes mellitus (T2DM) and prior delirium is unclear. This study compares the effectiveness of GLP-1 RAs and metformin in preventing dementia among patients with a history of delirium using an extensive healthcare database.

Methods

A retrospective cohort study was conducted from 2005 to 2025 using data from the TriNetX Global Federated Research Network. We identified adults aged 65 and older with T2DM and delirium, who received either GLP-1 RAs (exposure) or metformin (control). Propensity score matching (PSM) was performed. We determined dementia outcomes and all-cause mortality using Kaplan–Meier survival curves, Cox proportional hazards models, and estimated odds ratio (OR). Subgroup analyses were conducted by age, sex, race, body mass index (BMI), and dementia types.

Results

In a study involving 23,980 patients treated with GLP-1RAs and 23,980 matched patients treated with metformin, the mean age was 74 years, with 53% being female. The use of GLP-1RAs therapy was associated with a significantly lower risk of dementia compared to metformin among adults aged 65 years and older with T2DM with delirium with the adjusted hazard ratio (AHR) for dementia was 0.778 [95% confidence interval (CI): 0.736–0.822 p < 0.0001], and OR was 0.617 (95% CI: 0.582–0.655 p < 0.0001). The reduction in dementia risk varied by age, race, BMI, and dementia type. We observed a time-dependent decrease in mortality risk with GLP-1 RA users.

Conclusions

In older adults with T2DM and delirium, GLP-1 RA therapy was associated with a reduced risk of dementia compared with metformin. Variations in subgroups suggest individualized treatment. Prospective randomized controlled trials are needed to confirm these findings and clarify differential effects across various subgroups.

Zitieren

APA

Mercado, F., Akter, S., Ogawa, A., Ramakrishnan, S. V., & Suzuki, R. (2026). Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥ 65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025). Journal of Dementia and Alzheimer's Disease, 3(2), 24. https://doi.org/10.3390/jdad3020024

Vancouver

Mercado F, Akter S, Ogawa A, Ramakrishnan SV, Suzuki R. Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥ 65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025). Journal of Dementia and Alzheimer's Disease. 2026;3(2):24. doi:10.3390/jdad3020024

BibTeX
@article{Mercado2026,
  author = {Mercado, Francisco and Akter, Sumi and Ogawa, Aoi and Ramakrishnan, Subrahmanyan Valadi and Suzuki, Reannon},
  title = {Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥ 65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025)},
  journal = {Journal of Dementia and Alzheimer's Disease},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {24},
  doi = {10.3390/jdad3020024}
}
Kostenlos starten →